A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19

To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and safety of IFN β-1a were evaluated in patients with severe COVID-19. Forty-two patients in the interferon group r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Davoudi-Monfared, Effat, Rahmani, Hamid, Khalili, Hossein, Hajiabdolbaghi, Mahboubeh, Salehi, Mohamadreza, Abbasian, Ladan, Kazemzadeh, Hossein, Yekaninejad, Mir Saeed
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2020
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449227/
https://ncbi.nlm.nih.gov/pubmed/32661006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01061-20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky